Abdulhay Albirini, MD
Interventional Cardiology · Zanesville, OHNPI 1174509160
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (52.3%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 54 manufacturers reported payments, led by Shockwave Medical, Inc at 36.0% of the total. Reporting peaked in 2024 at $12,296 and has fallen 84.1% since, to $1,951 in 2025.
Across 608 payments — averaging $39.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Shockwave Medical, Inc$9K
- Abbott$3K
- Inari Medical, Inc.$2K
- Boston Scientific$2K
- Amgen$1K
- AstraZeneca$727
- plus $7K from 48 others
Across 88 payments — averaging $2428.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$140K
- CSL Behring$16K
- Novartis$14K
- Abbott$13K
- Boston Scientific$10K
- Boehringer Ingelheim Pharma GmbH & Co.kg$10K
- plus $11K from 2 others
What the payments were for
- Speaking & faculty fees$6,60027%
- Travel & lodging$4,81820%
- Food & beverage$12,63852%
- Education$1120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$8,233
- FLOWTRIEVER CATHETER, S$1,904
- CT THROMBECTOMY SYSTEM KIT$1,904
- OPTIS$1,214
- SUPERA$934
- Indigo System$386
- Vascular Lithotripsy$162
- OPTICROSS$150
- Impella$149
- GENERAL VASCULAR ACCESS$133
- VYNDAQEL$121
- SHOCKWAVE INTRAVASCULAR LITHOTRIPSY (IVL) SYSTEM WITH THE SHOCKWAVE C2+ CORONARY$120
- XARELTO$120
- BioMimics$105
How this compares
$24,168 in reported general payments places this provider in the 75th percentile of 256 interventional cardiology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 248 | $240,656 |
| Repatha SureclickEvolocumab | 202 | $158,146 |
| EntrestoSacubitril/Valsartan | 152 | $104,218 |
| XareltoRivaroxaban | 49 | $61,135 |
| Praluent PenAlirocumab | 60 | $43,903 |
| FarxigaDapagliflozin Propanediol | 38 | $19,326 |
| JardianceEmpagliflozin | 19 | $15,447 |
| BrilintaTicagrelor | 19 | $12,084 |
| Ezetimibe | 320 | $7,404 |
| Metoprolol Succinate | 680 | $6,268 |
| Atorvastatin Calcium | 636 | $5,185 |
| Ranolazine ErRanolazine | 33 | $4,660 |
| Nebivolol Hcl | 46 | $3,161 |
| Rosuvastatin Calcium | 298 | $2,952 |
| ClopidogrelClopidogrel Bisulfate | 294 | $2,398 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $498 | $240,656248 claims |
| NovartisEntresto | $549 | $104,218152 claims |
| Johnson & JohnsonXarelto | $601 | $61,13549 claims |
| AstraZenecaFarxiga, Brilinta | $727 | $31,40957 claims |
| Boehringer IngelheimJardiance | $62 | $15,44719 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 256 interventional cardiology providers in Ohio.
Other interventional cardiology in Zanesville
- Gary AnselColumbus$3.3M
- John CheathamColumbus$1.4M
- Carlos Sanchez SotoColumbus$1.1M
- Steven YakubovColumbus$907K
- Timothy HenryCincinnati$605K
- Mitchell SilverColumbus$562K
- John PhillipsColumbus$410K
- John CorlCincinnati$390K
- Santiago GarciaCincinnati$360K
- Atish MathurMansfield$291K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.